You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 27, 2024

LOREEV XR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Loreev Xr, and what generic alternatives are available?

Loreev Xr is a drug marketed by Almatica and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-five patent family members in thirty countries.

The generic ingredient in LOREEV XR is lorazepam. There are eleven drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the lorazepam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Loreev Xr

A generic version of LOREEV XR was approved as lorazepam by SANDOZ on April 21st, 1987.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for LOREEV XR?
  • What are the global sales for LOREEV XR?
  • What is Average Wholesale Price for LOREEV XR?
Summary for LOREEV XR
International Patents:35
US Patents:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 50
Patent Applications: 4,528
Drug Prices: Drug price information for LOREEV XR
What excipients (inactive ingredients) are in LOREEV XR?LOREEV XR excipients list
DailyMed Link:LOREEV XR at DailyMed
Drug patent expirations by year for LOREEV XR
Drug Prices for LOREEV XR

See drug prices for LOREEV XR

Pharmacology for LOREEV XR
Drug ClassBenzodiazepine

US Patents and Regulatory Information for LOREEV XR

LOREEV XR is protected by one US patents.

Patents protecting LOREEV XR

Sustained release formulations of lorazepam
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Almatica LOREEV XR lorazepam CAPSULE, EXTENDED RELEASE;ORAL 214826-001 Aug 27, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Almatica LOREEV XR lorazepam CAPSULE, EXTENDED RELEASE;ORAL 214826-003 Aug 27, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Almatica LOREEV XR lorazepam CAPSULE, EXTENDED RELEASE;ORAL 214826-004 Feb 16, 2022 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Almatica LOREEV XR lorazepam CAPSULE, EXTENDED RELEASE;ORAL 214826-002 Aug 27, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for LOREEV XR

See the table below for patents covering LOREEV XR around the world.

Country Patent Number Title Estimated Expiration
Poland 2943185 ⤷  Sign Up
Brazil 112015016304 formulações de lorazepam de liberação sustentada ⤷  Sign Up
Japan 2016504390 ロラゼパムの徐放性製剤 ⤷  Sign Up
Chile 2015001920 Formulaciones de lorazepam de liberación sostenida ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.